{"id":"NCT03581786","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","briefTitle":"The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer","officialTitle":"A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-18","primaryCompletion":"2020-05-30","completion":"2022-11-18","firstPosted":"2018-07-10","resultsPosted":"2022-04-18","lastUpdate":"2025-09-02"},"enrollment":289,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Recurrent or Metastatic NPC"],"interventions":[{"type":"BIOLOGICAL","name":"TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy","otherNames":[]},{"type":"DRUG","name":"Placebos","otherNames":[]}],"arms":[{"label":"placebo combine with chemotherapy","type":"PLACEBO_COMPARATOR"},{"label":"TORIPALIMAB INJECTION(JS001 )combine with chemotherapy","type":"EXPERIMENTAL"}],"summary":"This is a randomized, placebo-controlled, multi-center, double blinded, Phase III study to determine the efficacy and safety of TORIPALIMAB INJECTIO（JS001） in combination with gemcitabine/cisplatin compared with placebo in combination with gemcitabine/cisplatin as first-line treatment in patients with histological/cytological confirmation of recurrent or metastatic NPC. The primary endpoint is PFS in all patients. Approximately 280 patients who fulfill all of the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 ratio to one of the two treatment arms. patients will be randomly assigned to the combination of JS001 (Arm A) or placebo (Arm B) with gemcitabine and cisplatin given every 3 weeks (Q3W) in 3-week cycles.","primaryOutcome":{"measure":"IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1","timeFrame":"up to 2 years","effectByArm":[{"arm":"Placebo Combine With Chemotherapy","deltaMin":8.2,"sd":null},{"arm":"TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy","deltaMin":21.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":32,"countries":["China","Singapore","Taiwan"]},"refs":{"pmids":["38015220","34341578"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":62,"n":143},"commonTop":["Blood and lymphatic system disorders","Gastrointestinal disorders","Metabolism and nutrition disorders","General disorders and administration site conditions","Investigations"]}}